37043-68-8

Usage

Uses

Used in Pharmaceutical and Health Supplements:
5-aminopentanesulfonic acid is used as a health supplement for its role in supporting cardiovascular health, muscle function, and neurological processes. It is particularly beneficial for individuals seeking to improve athletic performance or manage certain health conditions.
Used in Energy Drinks:
In the food and beverage industry, 5-aminopentanesulfonic acid is used as an ingredient in energy drinks to provide potential health benefits and support metabolic processes, capitalizing on its presence in high-energy tissues and its role in energy production.
Used in Research and Development:
5-aminopentanesulfonic acid is utilized in scientific research as a model compound for studying various biological processes and mechanisms, given its involvement in antioxidant activity and its potential neuro-modulatory effects.
Used in Cosmetics and Personal Care Products:
In the cosmetics industry, 5-aminopentanesulfonic acid may be used as an ingredient for its antioxidant properties, potentially contributing to skin health and protection against oxidative stress.
Used in Veterinary Medicine:
5-aminopentanesulfonic acid is also used in veterinary applications to support the health of animals, particularly in relation to their cardiovascular and muscular systems, as well as overall metabolic health.

InChI:InChI=1/C5H13NO3S/c6-4-2-1-3-5-10(7,8)9/h1-6H2,(H,7,8,9)

Upstream product

• 74098-30-9 N-(5-chloropentyl)benzamide 
• 111-24-0 1,5-dibromo-pentane 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 776-75-0 N-benzoylpiperidine 

Downstream Products

• 55788-43-7 ε-Guanidinopentanesulfonic Acid 
• 1364083-80-6 C₃₅H₃₅NO₁₁S 

Relevant academic research and scientific papers

15 the position escapes acetylprotoaescigenin 13 bit linear amino sulfonic acid substituted hypocrellin derivative and its preparation method and application

The invention discloses a site-15 deacetylation and site-13 straight-chain sulfamic acid substituted hypocrellin derivative, a preparation method and application thereof. The structural general formula of the derivative is shown as the formula I (disclosed in the specification). The derivative is a novel hypocrellin derivative designed specially aiming at photodynamic medical treatment of micrangium diseases such as related retina macular degeneration, and the like. The maximum light absorption wavelength of the derivative is 58 nm, and the light tissue penetration depth in the wavelength range conforms to the focus depth of the micrangium diseases, meanwhile, the absorption spectrum of visual pigment is kept away as far as possible; and in addition, the derivative has optimized dual affiliation to fat and water and can be directly dissolved into normal saline to prepare intravenous injection solutions without complicated preparation technologies.

Quantitative and site-directed chemical modification of hypocrellins toward direct drug delivery and effective photodynamic activity

For photodynamic therapy (PDT) treatment of microvascular diseases, drugs are delivered via blood circulation and the targets are vasculature endothelial cells, for which the contradictory requirements of hydrophilicity and lipophilicity of the drugs have been achieved by liposome preparations. Herein, it is demonstrated that the drug delivery and target affinity are achieved by a single chemical compound, hypocrellin B (HB) derivative 6 selected from three novel aminoalkanesulfonic acid HB derivatives, 5-7. 6 exhibits a much higher PDT activity (IC50 = 22 nM) on human gastric carcinoma BGC823 cells than HB, while it has no cellular toxicity in the dark. On the basis of estimation of the clinically required concentration according to relative PDT activity and clinical criteria, it can be predicted that 6 is directly deliverable to and PDT effective on target cells. The enhanced red absorption and superhigh photoactivity suggest that 6 is more powerful for PDT of tumors than HB.

Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products

The present invention relates to a novel sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof. More particularly, the present invention relates to a sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof, which is useful as an inhibitor of lipopolysaccharides (LPS). In addition, the present invention relates to a novel intermediate compound useful for the synthesis of this sulfonic acid derivative of hydroxamic acid.

Probiotics. Antistaphylococcal and antifibrinolytic activities of omega amino and omega guanidinoalkanesulfonic acids

A series of ;. aminoalkanesulfonic acid and ω guanidinoalkanesulfonic acids was tested for antistaphylococcal and antifibrinolytic activities. Most of the former and one of the latter class gave better protection against Staphylococcus aureus infections in mice than 4 aminobutyryl L histidine. Most of the ω aminoalkanesulfonic acids showed antifibrinolytic activity, one of them having activity equal to or greater than that of aminocaproic acid, whereas none of the ω guanidinoalkanesulfonic acids had significant antifibrinolytic activity.